Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov58510.25208/vdv585ArticlesСтатьиResearch ArticleImmunohistochemistry detection of kappa-opioid receptors in human skinИммуногистохимическая детекция каппа-опиоидных рецепторов в коже человекаBobkoS IБобкоС И

аспирант

sbobko@mail.ruLottsT

к.б.н., научный сотрудник

MetzeD

профессор, зав. отделением дерматологии, гистологии и иммуногистохимии

LvovA NЛьвовА Н

д.м.н., профессор, заместитель директора по научно-клинической работе

StaenderSStänderS

профессор, зав. отделением дерматологии, руководитель компетентного центра по изучению хронического зуда

I.M. Sechenov First Moscow State Medical UniversityГБОУ ВПО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава РоссииCompetence Center for Chronic Pruritus, University Hospital for Skin Diseases, MuensterКомпетентный центр по изучению хронического зуда Университетской клиники кожных болезней г. МюнстераState Research Center of Dermatology, Venereology and Cosmetology, Ministry of Health Care of the Russian FederationФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России15022013891NO1 (2013)№1 (2013)303711032020Copyright ©; 2013, Bobko S.I., Lotts T., Metze D., Lvov A.N., Staender S.Copyright ©; 2013, Бобко С.И., Lotts T., Metze D., Львов А.Н., Ständer S.2013Bobko S.I., Lotts T., Metze D., Lvov A.N., Staender S.Бобко С.И., Lotts T., Metze D., Львов А.Н., Ständer S.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/585

The imbalance of p- and kappa-opioid receptors in the skin or central nervous system is currently deemed to be one of the reasons of chronic pruritus. A number of studies demonstrated a positive effect of system agonists of kappa-opioid receptors in the treatment of uremic pruritus, nodular pruritus, paraneoplastic and cholestatic pruritus. This research demonstrates an expression of kappa-opioid receptors in human skin (basal keratinocytes, dendritic cells, epidermal melanocytes and fibroblasts of the upper dermis) detected with the use of different immunochemistry methods.

В качестве одной из причин хронического зуда в настоящее время предполагается дисбаланс системы мю- и каппа-опиоидных рецепторов в коже или в центральной нервной системе. В нескольких исследованиях продемонстрирован положительный эффект системных агонистов каппа-опиоидных рецепторов в лечении уремического зуда, узловатой почесухи, паранеопластического и холестатического зуда. В настоящей работе демонстрируется экспрессия каппа-опиоидных рецепторов в коже человека (базальных кератиноцитах, дендритных клетках, меланоцитах эпидермиса и фибробластах сосочкового слоя дермы), определенная с помощью различных иммуногистохимических методик.

expression of kappa-opioid receptorspruritusagonists of kappa-opioid receptorsimmunochemistry studiesdynorphinэкспрессия каппа-опиоидных рецепторовзудагонисты каппа-опиоидных рецепторовиммуногистохимические исследованиядинорфинSatoh M., Minami M. Molecular pharmacology of the opioid receptor. Pharmacol Ther 1995; 68; 343—364.Zadina J.E., Martin-Schild S., Gerall A.A., Kastin A.J., Hackler L., Ge K.J., et al. Endomorphins: novel endogenous mu-opiate receptor agonists in regions of high mu-opiate receptor dencity. Ann NY ACAD Sci 1999; 897: 136—144.Stefano G.B., Goumon Y., Caseres F., Cadet P., Fricchione G.L., Rialas C. Et al. Endogenous morphine. Trends Neurosci 2000; 23: 436—442.Tseng R.J., Padgett D.A., Dhabhar F.S., Engler H., Sheridan J.F. Stress-induced modulation of NK activity during influenza viral infection: role of glucocorticoids and opioids. Brain Behav Immun 2005; 19: 153—164.Schwartz T.W., Holst B. Molecular structure of G-protein-coupled receptores. In: Foreman J.C., Johansen T., editors. Textbook of receptor pharmacology. New York: CRC Press 2002: 81—110.Tominaga M., Ogawa H., Takamori K. Possible roles of epidermal opioid system in pruritus of atopic dermatitis J Invest Dermatol 2007; 127; 2228—2235.Cheng B., Liu H.W., Fu X.B., Sheng Z.Y., Li J.F. Coexistence and upregulation of three types of opioid receptors, mu, delta and kappa, in human hypertrophic scars Br. J. Dermatol 2008; 158: 713—720.Salemi S., Aeschlimann A., Reisch N., Jüngel A., Gay R.E., Heppner F.L. et al. Detection of kappa and delta opioid receptors in skin — outside the nervous system. Biochem Biophys Res Commun 2005; 338: 1012—1017.Phan N.Q., Bernhard J.D., Luger T.A., Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol 2010; 63; 680—688.Pan ZZ mu-Opposing actions of the kappa-opioid receptor. Trend Pharmacol Sci 1998; 19: 94—98.Togashi Y., Umeuchi H., Okano K., Ando N., Yoshizawa Y., Honda T. et al. Antipruritic activity of the kappaopioid receptor agonist, TRK-820. Eur J Pharmacol 2002; 435: 259—264.Wilkström B., Gellert R., Ladefoged S.D., Danada Y., Akai M., Ide K. et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005; 16; 3742—3747.Mettang T., Pauli-Magnus C., Alscher D.M. Uraemic pruritus — new perspectives and insights from recent trial. Nephrol Dial Transplantant 2002; 17: 1558— 1563.Ikoma A., Steinhoff M., Ständer S., Yosipovitch G., Schmelz M. The neurobiology of itch. Nat Rev Neurosci 2006; 7: 535—546.Kumagai H., Matsukawa S., Utsumi J., Saruta T. Prospects for a novel kappa-opioid receptor agonist,TRK-820, in uremic pruritus. In: Yosipovitch G, editor. Itch. Basic mechanisms and therapy. New York, Marcel Dekker, 2004; 279—286.Kumagai H., Ebata T., Takamori K., Muramatsu T., Nakamoto H., Syzuki H. Effect of a novel kappa-receptor agonist nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, andomized, double-blind, placebo-controlled study. Nephrol Dial Transplantant 2010; 25; 1251—1257.Taneda K., Tominaga M., Negi O., Tengara S., Kamo A., Ogawa H. et al. Evaluation of epidermal nerve density and opioid receptor levels in psoriatric itch. Br. J Dermatol 2011; 165: 277—284.Finlay M.J., Chen X., Bardi G., Davey P., Geller E.B., Zhang L., et al. Bi-directional heterologous desensitization between the major HIV-1 co-receptor CXCR4 and the kappa-opioid receptor. J. Neuroimmunol 2008; 197: 114—123.Stein C., Hassan A.H., Przewlocki R., Gramsch C., Peter K., Herz A. Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci USA 1990; 87; 5935—9.Coggeshall R.E., Zhou S., Carlton S.M. Opioid receptors on peripheral sensory axons. Brain Res 1997; 764: 126—32.Kosterlitz H.W., Paterson S.J., Robson L.E. Characterization of the kappa-subtype of the opiate receptor in the guinea-pig brain Br. J. Pharmacol 1981; 73: 939—949.Zukin R.S., Eghbali M., Olive D., Unterwald E.M., Tempel A. Characterisation and visualisation of rat and guinea pig brain kappa opioid receptors: evidence for kappa 1 and kappa-opioid receptors. Proc Natl Acad Sci USA 1988; 85: 4061—4065.Clark J.A., Liu L., Price M., Hersch B., Edelson M., Pasternak G.W. Kappa opiate receptor multiplicity: evidence for two U50, 488-sensitive kappa 1 subtypes and a novel kappa 3 subtype. J Pharmacol Exp Ther 1989; 251: 461—468.Rothman R.B., Bykov V., de Costa B.R., Jacobson A.E., Rice K.C., Brady L.S. Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain. Peptides 1990; 11: 311—331.Zhu J., Chen C., Xue J.C., Kunapuli S., DeRiel J.K., Liu-Chen L.Y. Cloning of a human kappa opioid receptor from the brain. Life Sci 1995; 56: 201—207.Mansour A., Hoversten M.T., Taylor L.P., Watson S.J., Akil H. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res 1995; 700: 89—98.Simonin F., Gavériaux-Ruff C., Befort K., Matthes H., Lannes B., Micheletti G., et al. Kappa-opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci USA 1995; 92: 7006—7010.Bigliardi-Qi M., Gaveriaux-Ruff C., Pflatz K., Bady P., Baumann T., Rufli T., et al. Delection of mu- and kappa-opioid receptors in mice changes epidermal hypertrophy, density of peripheral nerve endings, and itch behavior. J Invest Dermatol 2007; 127: 1479—1488.Svingos A.L., Colago E.E. Kappa-opioid and NMDA glutamate receptors are differentially targeted within rat media prefrontal cortex. Brain Res 2002; 946: 262—271.Tempel A., Zukin R.S. Neuroanatomical patterns of mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro autoradiography. Proc Natl Acad Sci USA 1987; 84: 4308—4312.George S.R., Zastawny R.L., Ibriones-Urbina R., Chenge R., Nhuyen T., Heiber M, et al. Distinct distributions of mu, delta and kappa opioid receptor mRNA in rat brain. Biochem Biophys Res Common 1994; 205: 1438—1444.Mansour A., Fox C.A., Burke S., Meng F., Thompson R.C., Akil H. et al. Delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol 1994; 350: 412—438.Mansour A., Khachaturian H., Lewis M.E., Akil H., Watson S.J. Anatomy of CNS opioid reeptors. Trends Neurosci 1988; 11: 308—314.Okada-Ogawa A., Kurose M., Meng I.D. Attenuation of cannabinoid-induced inhibition of medullary dorsal horn neurons by a kappa-opioid receptor antagonist. Brain Res 2010; 1359: 81—89.Stein C., Lang K.J. Peripheral mechanisms of opioid analgesia. Curr Opin Pharmacol 2009; 9: 3—8.Rau K.K., Caudle R.M., Cooper B.Y., Johnson R.D. Diverse immunocytochemical expression of opioid receptors in electrophysiologically defined cells of rat dorsal root ganglia. J Chem Neuroanat 2005; 29: 255—264.Kamei J., Nagase H. Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated responce in mice. Eur J Pharmacol 2001; 418: 141—145.Inan S., Dun N.J., Cowan A. Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-foc expression and attenuates 5'-guanidinonaltrindoleelicited scratching nehavior in mice. Neuroscience 2009; 163: 23—33.Nakao K., Ikeda K., Kurokawa T., Togashi Y., Umeuchi H., Honda T. et al. Effect of TRK-820, a selective kappa-opioid receptor agonist, on scratching behaviour in an animal model of atopic dermatitis. Nihon Shinkei Seishin Yakurigaku Zasshi 2008; 28: 75—83.Umeuchi H., Togashi Y., Honda T., Nakao K., Okano K., Tanaka T., et al. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by activation of kappa-opioid system. Eur J Pharmacol 2003; 477: 29—35.Wang Y., Tang K., Inan S., Siebert D., Holzgrabe U., Lee D.Y., et al. Comparison of pharmacological activities of free distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa-opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 2005; 312: 220—230.Umeuchi H., Kawashima Y., Aoki C.A., Kurokawa T., Nakao K., Itoh M., et al. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride. Eur J Pharmacol 2005; 518: 133—139.Inan S., Cowan A. Nalfurafine, a kappa-opioid receptor agonist inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats. Pharmacol Biochem Behav 2006; 85: 39—43.Wakasa Y., Fujiwara A., Umeuchi H., Endoh T., Okano K., Tanaka T. et al. Inhibitory effects of TRK-820 on systemic slin scratching induced by morphine in rhesus monkeys. Life Sci 2004; 75: 2947—2957.Seki T., Awamura S., Kimura C., Ide S., Sakano K., Minami M. et al. Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor. J Pharmacol 1999; 376: 159—167.Lawhorn C.D., McNitt J.D., Fibuch E.E., Joyce J.T., Leadley R.J. Jr. Epidural morphine with butorphanol for postoperative analgesia after cesarean delivery. Anesth Analg 1991; 72: 53—57.Yeh Y.C., Lin T.F., Lin F.S., Wang Y.P., Lin C.J., Sun W.Z. Combination of opioid agonist and agonistantagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admictures for postoperative pain. Br J Anaesth 2008; 101: 542—548.Tamdee D., Charuluxananan S., Punjasawaswong Y., Tawichasri C., Patumanond J., Sriprajittichai P. A randomized controlled trial of penthazocine versus ondansetron for the treatment of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. Anesth Analg 2009; 109: 1606—1611.Bergasa N.V. Treatment of the Pruritus of cholestasis. Curr Tret Options Gastroenterol 2004; 7: 501—508.Dawn A.G., Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006; 54: 527—531.Ko M.C., Husbands S.M. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther 2009 Jan; 328(1): 193—200.Lee H., Naughton N.N., Woods J.H., Ko M.C. Effects of butorphanol on morphine-induced itch and analgesia in primates. Anesthesiology 2007 Sep; 107(3): 478—85.Ko M.C., Lee H., Song M.S., Sobczyk-Kojiro K., Mosberg H.I., Kishioka S., Woods J.H., Naughton N.N. Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther. 2003 Apr; 305(1): 173—9.Andoh T., Jagate J., Takeshima H., Kuraishi Y. Intradermal nociception elicits itch-associated responces through leukotriene B (4) in mice. J. Invest Dermatol 2004 Juli; 123 (1): 196—201.Bigliardi P.L., Büchner S., Rufli T., Bigliardi-Qi M. Specific stimulation of migration of human keratino-cytes by mu-opioid receptor agonists. J Recept Signal Transduct Res. 2002 Feb-Nov; 22 (1—4): 191—9.Chahl L.A., Chahl J.S. Plasma extravasation induced by dynorphin-(1—13) in rat skin. Eur J Pharmacol 1986 May 27; 124 (3): 343—7.